Single institution retrospective study of infusional etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, (EPOCH) +/- rituximab (R) as first line therapy for aggressive non-Hodgkin lymphoma.

e19514 Background: Standard treatment for aggressive NHL (aNHL) is R-CHOP in B cell lymphomas and CHOP in T cell lymphomas. A significant proportion of patients; however, ultimately die from their disease. To improve outcomes, novel chemotherapy combinations, dosing schedules and strategies have been used. We describe 136 patients with untreated aNHL treated with infusional dose adjusted EPOCH (DA- EPOCH) chemotherapy +/- R in the first line setting. Methods: We screened 138 patients using the tumor registry. Inclusion criteria included diagnosis of aNHL and first line treatment with EPOCH +/-R given from 2005-2013. Exclusion criteria: primary CNS lymphoma and CTCL not requiring therapy. Results: 136 patients met inclusion criteria. 112 (82%) B-cell and 24 (18%) T-cell NHL. 102 (75%) patients were stage III/IV and 34 (25%) were stage I/II. The median duration of follow up was 27 months and 62 (55%) patients completed six or more cycles. The ORR was 82%. 90 patients achieved CR, (76 B-cell and 14 T-cell); ...